This article is more than 5 years old. Information may no longer be current.

Apraglutide receives orphan drug designation for short bowel syndrome

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The European Commission has granted an orphan drug designation to Therachon’s apraglutide for the treatment of short bowel syndrome, according to a company press release.

Apraglutide (FE 203799) – a next-generation, synthetic GLP-2 analog – has demonstrated a superior pharmacokinetic profile with a half-life of 30 hours across multiple phase 1 single ascending dose/multiple ascending dose clinical trials in healthy volunteers, according to the release.

Two phase 2 clinical trials are currently evaluating the use of apraglutide in patients with short bowel syndrome.

“We are pleased to receive this designation, which was granted upon reviewing both preclinical study results from ... phase 2 clinical trial data obtained with weekly dosing of apraglutide in patients with short bowel syndrome,” Luca Santarelli, MD, CEO of Therachon, said in the release. “We believe that apraglutide’s orphan drug designation is consistent with its potential to become the best-in-class therapeutic for the treatment of SBS.”